FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A phase 2 trial of FPI-2265, Olaparib in prostate cancer, run by Fusion Pharmaceuticals Inc., active and no longer recruiting.
Overview
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) is a phase 2 interventional study registered as NCT06909825 by Fusion Pharmaceuticals Inc., with 85 participants planned, started 2025-02-26 and due to reach its primary completion in 2027-05. Interventions recorded: FPI-2265, Olaparib. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialTargeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
Shares FPI-2265, AstraZeneca, Metastatic castration-resistant prostate cancer, Prostate cancer.
- TrialAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Shares FPI-2265, AstraZeneca, Metastatic castration-resistant prostate cancer, Actinium-225.
- TrialPhase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Shares FPI-2265, AstraZeneca, Actinium-225, Prostate cancer.
- IdeaAdding a PARP inhibitor to PSMA radioligand therapy
Shares Olaparib, FPI-2265, Metastatic castration-resistant prostate cancer, Actinium-225.
- AgentActinium-225 FPI-2068
Shares FPI-2265, AstraZeneca, Actinium-225.
- TrialAlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)
Shares AstraZeneca, Metastatic castration-resistant prostate cancer, Actinium-225, Prostate cancer.
- TrialA Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
- Pairing177Lu-PSMA-617 (Pluvicto) with olaparib
Shares Olaparib, Metastatic castration-resistant prostate cancer, Actinium-225.